HeraMED Limited announced that the clinical study at the Joondalup Health Campus in Western Australia, is on track and provides the following progress report. In an important step, the Study has now been registered on the Australian and New Zealand Clinical Trial Register (ANZCTR) and can be found here. The recruitment of participants has now commenced. The Study is recruiting 60 expectant mothers over the age of 18 years with a singleton pregnancy from 12 weeks gestation and is attending the Joondalup Health Campus antenatal clinic. This represents an important step forward for the Study and HMD as it enables the researchers to collect and analyse the data including accuracy, user-friendliness, and user's satisfaction, providing further clinical validation for its solutions and setting a new standard of care in remote, foetal and maternal wellbeing. Next Steps: Step 1, which has already commenced, includes the recruitment of participants and assessment by clinical staff (JHC antenatal clinic), evaluating accuracy levels by a professional comparing the HeraBEAT to a hospital CTG machine. Step 2, includes use and assessment by the expectant mother, evaluating usability, ease of use and user satisfaction at the clinic and measured by the international medical standard System Usability Scale (SUS). Step 3 highlights and evaluates remote home monitoring; using the HeraBEAT device for recording continuous FHR trace by the mother, electronically transmitted to the obstetrician/midwife for review and consultations. An assessment of the transmission, including data clarity and clinical utility, will be made by the antenatal team. It is estimated that the study will complete within 2 months.